Robins Kaplan LLP is among the nation’s premier trial law firms, with more than 225 attorneys in seven major cities. Our attorneys litigate, mediate, and arbitrate client disputes, always at-the-ready for an ultimate courtroom battle. When huge forces are at play, major money is at stake,...
Robins Kaplan LLP + Follow Contact Popular Topics by This Author Acquisitions Arbitration Continuing Legal Education Contract Disputes Contract Drafting Contract Negotiations Corporate Counsel Intellectual Property Litigation Intellectual Property Protection IP License See more...
Latest publications and contact information for attorney Aaron Fahrenkrog at Robins Kaplan LLP via law news provider JD Supra.
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising. © Robins Kaplan LLP 2024 ...
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising. © Robins Kaplan LLP 2024 ...
NAMIC AND APCIA STRENUOUSLY OPPOSE THE RESTATEMENT, AS SEVERAL STATES’ LEGISLATURES REJECT IT AS INCONSISTENT WITH THEIR JURISDICTIONS’ LAW AND POLICY. In May 2018, the long, contentious debate over the substance of the American Law Institute’s (ALI’s) proposed Restatement of the Law, ...
BECAUSE TAKEDA COULD NOT SHOW A LIKELIHOOD OF SUCCESS ON THE MERITS OR THAT IT WOULD SUFFER IRREPARABLE HARM, THE COURT DENIED ITS MOTION FOR A PRELIMINARY INJUNCTION. Case Name: Takeda Pharms. U.S.A., Inc. v. Mylan Pharms., Inc., No. 19-2216-RGA, 2020 U.S. Dist. LEXIS 12753 ...
Collegium filed for summary judgment, arguing that: (i) the ’933 patent is invalid under issue preclusion; (ii) it cannot infringe the ’933 patent because its product does not contain oxycodone hydrochloride; and (iii) it cannot infringe the irritant patents because its product does not ...
ANDA Approvals - Summer 2020 DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising. © Robins Kaplan LLP 2024 Writ...
The Federal Circuit further held that the district court’s invalidity determinations as to the asserted claims of the ’287 and ’062 patents were not in accordance with law. Accordingly, the Federal Circuit affirmed in part and reversed in part. Why Barr Prevailed: Alcon attempted to prove ...